Sign up for kodicms's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Sun Pharma announced its results for the second quarter ended September 2017 (2QFY18). While revenues (including operating revenues) fell by 19.5% YoY, net profits plunged 60% YoY.
|Other operating revenues||5,110||603||-88.2%||7,605||1,024||-86.5%|
|Operating profit (EBIDTA)||31,677||13,756||-56.6%||60,887||24,713||-59.4%|
|Operating profit margin (%)||38.3%||20.7%||36.9%||19.2%|
|Profit before tax||29,295||11,144||-62.0%||55,570||19,059||-65.7%|
|Profit after tax/ (loss)||24,711||10,018||-59.5%||47,388||6,792||-85.7%|
|Net profit margin (%)||31.9%||15.2%||30.1%||5.3%|
|No. of shares (m)||2,399.3|
|Diluted earnings per share (Rs)*||19.7|
|P/E ratio (x)||26.2|
* on a trailing twelve months basis excluding extraordinary items
|DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
kodicms Agora Research Private Limited (hereinafter referred to as "kodicms"/"Company") was incorporated on October 25, 2007. kodicms is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. kodicms is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537.
An independent research initiative, kodicms is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes.
There are no outstanding litigations against the Company, it subsidiaries and its Directors.
GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT:
For the terms and conditions for research reports
DETAILS OF ASSOCIATES:
Details of Associates are
DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us.